NANOVIRICIDES, INC.
Financial highlights
| Metric | FY 06/30/25 | FY 06/30/24 | FY 06/30/23 | FY 06/30/22 | FY 06/30/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $0 | $0 | $0 | — | — |
| Research and development | $5.5M | $5.4M | $6.4M | $5.8M | $6.1M |
| Operating expenses | $9.6M | $8.5M | $8.9M | $8.1M | $8.7M |
| Operating income | -$9.6M | -$8.5M | -$8.9M | -$8.1M | -$8.7M |
| Interest expense | $149 | $49,808 | $938 | $5,123 | $85,405 |
| Pretax income | — | — | — | -$8.1M | -$8.8M |
| Income tax expense | $0 | $0 | $0 | $0 | $0 |
| Net income | -$9.5M | -$8.3M | -$8.6M | -$8.1M | -$8.8M |
| Balance Sheet | |||||
| Cash and equivalents | $1.6M | $4.8M | $8.1M | $14.1M | $20.5M |
| Current assets | $1.7M | $5.0M | $8.4M | $14.4M | $20.8M |
| Total assets | $8.8M | $12.8M | $16.9M | $23.5M | $30.3M |
| Current liabilities | $1.3M | $1.4M | $534,250 | $412,837 | $351,146 |
| Total liabilities | $1.3M | $1.4M | $2.0M | $412,837 | — |
| Stockholders' equity | $7.5M | $11.5M | $14.9M | $23.1M | $29.9M |
| Cash Flow Statement | |||||
| Cash from operations | -$8.5M | -$6.3M | -$5.7M | -$5.9M | -$8.2M |
| Depreciation and amortization | $735,536 | $750,744 | $739,259 | $715,055 | $696,268 |
| Stock-based compensation | — | $563 | $44,000 | — | $0 |
| Capital expenditure | $56,964 | $156,560 | $151,712 | $324,348 | $238,765 |
| Free cash flow | -$8.5M | -$6.5M | -$5.8M | -$6.2M | -$8.5M |
Shares outstanding 21.6M · Free float 45.1%
Annual filing data through FY ended June 30, 2025; float as of July 13, 2026.